Lifecore Biomedical (Lifecore Biomedical) Total Inventories : $40.8 Mil (As of May. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Total Inventories?

Lifecore Biomedical's total inventories for the quarter that ended in May. 2023 was $40.8 Mil. Lifecore Biomedical's average total inventories from the quarter that ended in Feb. 2023 to the quarter that ended in May. 2023 was $44.8 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Lifecore Biomedical's Net-Net Working Capital per share for the quarter that ended in May. 2023 was $-6.66.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Lifecore Biomedical's Days Inventory for the three months ended in May. 2023 was 238.81.

Inventory Turnover measures how fast the company turns over its inventory within a year. Lifecore Biomedical's Inventory Turnover for the quarter that ended in May. 2023 was 0.38.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Lifecore Biomedical's Inventory-to-Revenue for the quarter that ended in May. 2023 was 1.75.

Lifecore Biomedical Total Inventories Historical Data

The historical data trend for Lifecore Biomedical's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Total Inventories Chart

Lifecore Biomedical Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Total Inventories

Get a 7-Day Free Trial

54.13

66.31

63.08

36.00

40.84

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
Total Inventories	Get a 7-Day Free Trial															36.00	64.29	77.52	48.70	40.84

Lifecore Biomedical Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Lifecore Biomedical (NAS:LFCR) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Lifecore Biomedical's Net-Net Working Capital Per Share for the quarter that ended in May. 2023 is

	Net-Net Working Capital Per Share (Q: May. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(19.091	+	0.75 * 29.024	+	0.5 * 40.841	-	257.775
-	0	-	0)	/	29.513
=	-6.66

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lifecore Biomedical's Days Inventory for the three months ended in May. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: May. 2023 )	/	Cost of Goods Sold (Q: May. 2023 )	*	Days in Period
	=	44.7685	/	17.106	*	365 / 4
	=	238.81

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lifecore Biomedical's Inventory Turnover for the quarter that ended in May. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: May. 2023 )	/	Average Total Inventories (Q: May. 2023 )
	=	17.106	/	44.7685
	=	0.38

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lifecore Biomedical's Inventory to Revenue for the quarter that ended in May. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: May. 2023 )	/	Revenue (Q: May. 2023 )
	=	44.7685	/	25.521
	=	1.75

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Lifecore Biomedical Total Inventories Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (Lifecore Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

3515 Lyman Boulevard, Chaska, MN, USA, 55318

Website

https://www.lifecore.com

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.

Executives

Raymond T. White	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper	director	12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian	director	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter	director	C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg	officer: Chief Financial Officer	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles	director	CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall	officer: Executive Vice President	3515 LYMAN BLVD., CHASKA MN 55318